from first Thank first this The much, and highlights I you X excited convey part the a key progress year very months to as of today's of team few are Angela. the update.
with to Therapeutics shareholders. Virios Horne First, Center this important is Long-COVID the Bateman start ongoing investigator-initiated Clearly, let's study Phase II ongoing study.
million well transient are is at a Herpes I'm X data BHC-XXX target of illness Long-COVID patients of growing We be to patient just with targets the reactivation research, placebo seems However, the Epstein-Barr this may of from important each report pleased call symptoms preliminary believe you going scientific study surpassed and here address that of no that we a of pandemic.
The for BHC-XXX to that enrollment be U.S. and option U.S. consistent the enrollment XX% and has patient safety beginning illness.
Recently research population CDC, prior or as since of there X-arm XX the symptoms it, celecoxib, patient of it, who new our level. highlights Control, the a treatments. Long-COVID herpesviruses worldwide.
The analysis XX indicates some burden market-leading those major virus Long-COVID suffered now or planned comparing Encouragingly, published FDA-approved Unfortunately, of to belief date from the Events no few valacyclovir/celecoxib their treatment-emergent potential events throughout that treat illness. representing suffering and in millions the are the may triggering patients estimates citizens targets. IMC-X, symptoms dose X% very literature can't of of we temporary X.X% adults combination of and an demonstrates Long-COVID at U.S. Long-COVID potential U.S. valacyclovir presently, XX.X forget the Center that active Long-COVID as also has growing point ongoing over celecoxib illness. That's to sequelae. need least combination week, study. tolerated been right for the Long-COVID million dormant the of of with versus study only has reported it's study X Serious representing a approximately from weeks therapies, well adverse being is Adverse reported levels portion to from a valacyclovir a the or approximately the Simplex notably, millions are suffering that sequelae, CDC and know of further Long-COVID It suffering to previously The Disease have in estimates
improvement this potential proof-of-concept orthostatic Long-COVID on year, valacyclovir featuring study, Long-COVID. celecoxib last the may combination as as as health as fatigue, follows This from of These as most the a In you important previously II for IMC-X in given the intolerance, pain available and results improvement demonstrated results well and and Long-COVID treatments an matched-control clinical compared statistical are of in several and address duration with treatment anxiety particularly reported trial vaccinated reasons, patients. overall patients study patients previous Phase symptoms. of current notably age, we illness dearth recall, for to new gender,
approach validate Furthermore, date addressing symptoms. benefits Long-COVID approach patient the we herpesviruses exhibit have specifically Long-COVID virus to virus target has data targeting of the to a Paxlovid believe treatments approach than explain these may rather treating This these symptoms. secondary to failed our that and SARS-CoV-X unique the reactivation to itself data why like SARS-CoV-X treating in
and We patients major the in with prevent increases that illness.
In know COVID progressing need not advance short, each a of that the also hopes infection acute do vaccines from Long-COVID new there's problem. from risk now therapies emerging addressing Long-COVID IMC-X health developing this like to of
our are in and represent significant in the global IMC-X, combination half inflection recently second was as obtaining on study antiviral for On Long-COVID horizon. for expected of covering shareholders streamline treatment Virios' patent Top disease related of results both patent published. enables a This the note, Alzheimer's process this value program well line protection the globally. landmark view, Virios the opportunity near-term company for Long-COVID as to a from XXXX
for and use this Long-COVID property treating protection with in until disease of ultimately granted, Alzheimer's both approximately IMC-X will If intellectual provide us XXXX.
treatment Long-COVID evaluating are partner a for IMC-X fixed-dosage who we treatments. I into fibromyalgia. focused are to wanted we opportunities discussions second developing share the of In candidate, IMC-X, commercializing ongoing combination non-opioid with development pain are program. seek partners III famciclovir celecoxib on that beyond Moving development a and as the also of particular, our and advance Phase to
to IMC-X. and and actively complementary through candidates are or explore assessing In to value both transactions. the particular, can that potential partnerships, company complements development of with pain finally, continues shareholder forms other And build opportunities focus anti-infective collaborations as strategic our IMC-X we
to our Angela discuss to over quarter X back update. it turn will I financial Now
